PharmacyCodes



Nabumetonum [INN-Latin] en es it fr

Nabumetonum [INN-Latin] Brand names, Nabumetonum [INN-Latin] Analogs

Nabumetonum [INN-Latin] Brand Names Mixture

  • No information avaliable

Nabumetonum [INN-Latin] Chemical_Formula

C12H12N2O3

Nabumetonum [INN-Latin] RX_link

http://www.rxlist.com/cgi/generic2/nalidixicacid.htm

Nabumetonum [INN-Latin] fda sheet

Nabumetonum_[INN-Latin] FDA

Nabumetonum [INN-Latin] msds (material safety sheet)

Nabumetonum_[INN-Latin] MSDS

Nabumetonum [INN-Latin] Synthesis Reference

No information avaliable

Nabumetonum [INN-Latin] Molecular Weight

232.235 g/mol

Nabumetonum [INN-Latin] Melting Point

229.5 oC

Nabumetonum [INN-Latin] H2O Solubility

100 mg/L

Nabumetonum [INN-Latin] State

Solid

Nabumetonum [INN-Latin] LogP

0.949

Nabumetonum [INN-Latin] Dosage Forms

Suspension (250 mg/5 mL tsp); Tablets (1000 mg, 500 mg, 250 mg)

Nabumetonum [INN-Latin] Indication

For the treatment of urinary tract infections caused by susceptible gram-negative microorganisms, including the majority of E. Coli, Enterobacter species, Klebsiella species, and Proteus species.

Nabumetonum [INN-Latin] Pharmacology

Nalidixic acid is a quinolone antibacterial agent for oral administration. Nalidixic acid has marked antibacterial activity against gram-negative bacteria including Enterobacter species, Escherichia coli, Morganella Morganii; Proteus Mirabilis, Proteus vulgaris, and Providencia rettgeri. Pseudomonas species are generally resistant to the drug. Nalidixic acid is bactericidal and is effective over the entire urinary pH range. Conventional chromosomal resistance to nalidixic acid taken in full dosage has been reported to emerge in approximately 2 to 14 percent of patients during treatment; however, bacterial resistance to nalidixic acid has not been shown to be transferable via R factor.

Nabumetonum [INN-Latin] Absorption

Following oral administration, nalidixic acid is rapidly absorbed from the gastrointestinal tract. Bioavailability is approximately 96%. Absorption may be delayed if taken with antacids.

Nabumetonum [INN-Latin] side effects and Toxicity

ORAL (LD50): Acute: 1160 mg/kg [Rat]. 572 mg/kg [Mouse]. Toxic psychosis, convulsions, increased intracranial pressure, or metabolic acidosis may occur in patients taking more than the recommended dosage. Vomiting, nausea, and lethargy may also occur following overdosage.

Nabumetonum [INN-Latin] Patient Information

Nabumetonum [INN-Latin] Organisms Affected

Enteric bacteria and other eubacteria